Tytuł pozycji:
Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
-
Tytuł:
-
Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
-
Autorzy:
-
Mary A; Clinical Critical Care Pharmacy Department, Amiens-Picardie University Hospital, Amiens, France.; UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France.
Hénaut L; UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France.
Schmit JL; Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France.; AGIR UR UPJV 4294, CURS, University of Picardie Jules Verne, Amiens, France.
Lanoix JP; Infectious Diseases Department, Amiens-Picardie University Hospital, Amiens, France.; AGIR UR UPJV 4294, CURS, University of Picardie Jules Verne, Amiens, France.
Brazier M; UR UPJV 7517, MP3CV, CURS, University of Picardie Jules Verne, Amiens, France.; Department of Biochemistry, Amiens-Picardie University Hospital, Amiens, France.
-
Źródło:
-
Frontiers in public health [Front Public Health] 2020 May 15; Vol. 8, pp. 185. Date of Electronic Publication: 2020 May 15 (Print Publication: 2020).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Lausanne : Frontiers Editorial Office
-
MeSH Terms:
-
Nebulizers and Vaporizers*
COVID-19/*therapy
Interferon Type I/*administration & dosage
Antimalarials/therapeutic use ; Humans ; Hydroxychloroquine/administration & dosage ; SARS-CoV-2/isolation & purification
-
References:
-
JAMA. 2020 Apr 7;323(13):1239-1242. (PMID: 32091533)
Front Immunol. 2019 Jun 04;10:1261. (PMID: 31214198)
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. (PMID: 32391667)
Eur Respir J. 2010 Sep;36(3):646-54. (PMID: 20150207)
BMJ. 2020 Mar 26;368:m1252. (PMID: 32217607)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
Biosci Trends. 2020 Mar 16;14(1):72-73. (PMID: 32074550)
Travel Med Infect Dis. 2020 Mar - Apr;34:101663. (PMID: 32289548)
Cell Discov. 2020 Mar 18;6:16. (PMID: 32194981)
Int Immunopharmacol. 2016 Nov;40:318-326. (PMID: 27664570)
BMJ. 2020 Mar 26;368:m1091. (PMID: 32217556)
Aliment Pharmacol Ther. 2009 May 1;29(9):1000-10. (PMID: 19210290)
Lancet. 2020 Mar 28;395(10229):1033-1034. (PMID: 32192578)
Crit Care. 2020 Feb 19;24(1):56. (PMID: 32070391)
Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204)
Front Immunol. 2014 Sep 11;5:431. (PMID: 25309533)
Sci Rep. 2016 Jun 28;6:28698. (PMID: 27350308)
Hepatology. 2010 Oct;52(4):1225-31. (PMID: 20830784)
J Antimicrob Chemother. 2016 Oct;71(10):2767-81. (PMID: 27494903)
Viruses. 2019 Jan 14;11(1):. (PMID: 30646565)
Nat Rev Immunol. 2015 Feb;15(2):87-103. (PMID: 25614319)
Clin Infect Dis. 2006 Jun 15;42(12):1674-8. (PMID: 16705570)
JAMA. 2015 Nov 17;314(19):2034-2044. (PMID: 26575060)
JAKSTAT. 2013 Jan 1;2(1):e23820. (PMID: 24058799)
J Infect Dis. 2004 Apr 1;189(7):1164-7. (PMID: 15031783)
-
Contributed Indexing:
-
Keywords: COVID-19; SARS-CoV-2; azithromycin; hydroxychloroquine; type I interferon
-
Substance Nomenclature:
-
0 (Antimalarials)
0 (Interferon Type I)
4QWG6N8QKH (Hydroxychloroquine)
-
Entry Date(s):
-
Date Created: 20200624 Date Completed: 20201230 Latest Revision: 20231111
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7243823
-
DOI:
-
10.3389/fpubh.2020.00185
-
PMID:
-
32574289
-